Drugs / SGN-ALPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05229900 | Apr 2022 → Dec 2023 | endometrium neoplasm, gastric neoplasm, gastroesophageal cancer, neoplasm of testis +3 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-ALPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05229900 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT05229900 ↗ |